Рання діагностика раку грудей (англійською)
Which Cancer Tests Do You Really Need?
From the WebMD Archives
Feb. 1, 2013 -- Not all cancer screening tests are helpful, and some are potentially harmful, according to a new Consumer Reports rating.
In the new report, Consumer Reports recommends only three of 11 common cancer screening tests, and then only for certain age groups.
"The science of prevention and screening has changed," says John Santa, MD, MPH, director of the Consumer Reports Health Ratings Center. He oversaw the project.
"Consumers need to know that some screening tests are terrific, some are not good, and some can harm you," Santa says.
Continue Reading Below
you might like
"We are not talking about people at high risk," he says. "And of course they are not symptomatic. We're not talking about what you should do if you have a mole that is changing or if you feel a breast lump."
The full report is in the March issue of Consumer Reports.
To develop the ratings, Santa and his team looked at medical research, consulted medical experts, surveyed more than 10,000 readers, and talked with patients about screening tests.
They looked closely at recommendations of the U.S. Preventive Services Task Force. This independent panel provides guidelines on health care based on evidence. Much of Consumer Reports' recommendations follow the task force guidelines to the letter. But, their recommendations sometimes differ from those of organizations such as the American Cancer Society (ACS). Here, details on the three recommended tests:
· Cervical cancer . Women 21 to 30 should have a Pap smear to test for cervical cancer every three years. Women 30 to 65 can wait five years if they have had testing for human papillomavirus (HPV), the virus that causes the cancer. Those 65-plus can skip screening if they were screened regularly earlier. Those under 21 can also skip the test, as experts know the cancer is not common at those ages.
· Colon cancer. Those 50 to 75 should get screened regularly, and older people should discuss the pros and cons with their doctor and decide. Options include a colonoscopy, which examines the entire colon, every 10 years, or a sigmoidoscopy, which looks at the lower third, every five years plus a stool test every three years, or an annual stool test. As far as other guidelines, no groups suggest screening younger than 50 unless high risk. The ACS also doesn't say to specifically stop at age 75.
· Breast cancer . Women 50 to 75 need a mammogram every two years. Those 40 to 49 or 75 and older should talk with their doctor about pros and cons. These guidelines do split with those of the ACS, though. The cancer society recommends yearly mammograms after age 40 and as long as healthy.
Which Cancer Tests Do You Really Need?
From the WebMD Archives
The other eight tests were not recommended for those not at high risk because the cancers are uncommon, the test's effectiveness is not proven, or the test can't detect the disease at a curable stage. And even though some of the tests aren't really recommended by anyone, this list is a valuable reminder for people who may feel they need to seek them out.
On the "avoid" list, screenings for:
Continue Reading Below
· Pancreatic cancer. Tests are abdominal images or genetic tests. This test is also generally not recommended by anyone for the general public.
The new ratings drew mixed reactions.
Otis Brawley, MD, chief medical officer of the American Cancer Society, says the report helps to put screening into its proper perspective. "There has been a significant amount of over-promising and over-promoting," he says.
He frowns on aggressive campaigns that have included mammogram parties or group colonoscopies.
Which Cancer Tests Do You Really Need?
From the WebMD Archives
"A lot of screening is being done by organizations that can profit from it," he says.
"The truth is, certain tests do have some significant benefit, and every test has some limitations," he says. "In the spirit of informed decision-making, people need to understand both the potential for benefit and the potential for harm."
As mentioned, the recommendations on breast cancer screening from Consumer Reports and the American Cancer Society are different, but Brawley calls these differences ''minimal."
"We recommend women in their 40s get a mammogram on an annual basis, but we also recommend those women get information on the limitations," he says.
These include missing some cancers and ordering additional tests when no cancer turns out to be there.
Some doctors took issue with the decision to use the task force recommendations as the basic source.
Continue Reading Below
you might like
"I'm disappointed they followed the task force guidelines, because we feel they are inadequate to protect women," says Debra Monticciolo, MD, chair of the American College of Radiology's Quality and Safety Commission and vice chair of radiology at Scott & White Healthcare in Temple, Texas.
"Right now, we can't cure breast cancer, so we really need to find cancers early," she says. Research has found the best way to do that is by yearly mammograms beginning at age 40, she says.
The recommendation to avoid PSA tests refutes evidence that they work, say Dipen Parekh, MD, a professor and chair of urology at the University of Miami Miller School of Medicine's Sylvester Comprehensive Cancer Center.
"There is no question the decline in the incidence of advanced prostate cancer is due in large part to PSA screening," he says.
However, the recommendation for women at low risk for ovarian cancer not to seek screening is a good one, says J. Matt Pearson, MD, assistant professor and a gynecologic oncologist at the University of Miami Miller School of Medicine's Sylvester Comprehensive Cancer Center.
The lifetime risk of ovarian cancer in the general population is low. When you screen for a cancer that is not common, he tells women, "you are more likely to find a benign abnormality that pushes you toward [unneeded] surgery."
Santa recommends educating yourself about cancer screening tests, then talking to your doctor about whether the benefits outweigh the risks for you.
"Don't go to a mobile van, don't go to a mammogram party," he says.
"Don't believe a billboard on the highway that tells you to get a PSA test when it comes from a hospital that has a robotic prostate cancer surgery program."
Continue Reading Below
you might like
"If you are serious about preventing cancer, you don't smoke, you exercise, and you try to get to a normal weight," Santa says. Obesity has been linked with about 4% of men's new cancers and 7% of women's, he says.
Getting to a normal weight may especially lower the risk for uterine and esophageal cancers.
Also of Interest
· (Quiz) Uterine and Vaginal Prolapse
· (Video) Overview of Placenta Previa
By Mary Ann Kosir, MD, Professor of Surgery and Oncology;, Wayne State University School of Medicine;Karmanos Cancer Center
· Breast Disorders
· Breast Cancer
Breast cancer most often involves glandular breast cells in the ducts or lobules. Most patients present with an asymptomatic mass discovered during examination or screening mammography. Diagnosis is confirmed by biopsy. Treatment usually includes surgical excision, often with radiation therapy, with or without adjuvant chemotherapy, hormonal therapy, or both.
In the US, breast cancer is the 2nd leading cause of cancer death in white, black, Asian/Pacific Islander, and American Indian/Alaska Native women (after lung/bronchial cancer) but is the leading cause of cancer death among Hispanic women (1).
About 253,000 new cases of invasive breast cancer and about 41,000 deaths from it are expected in 2017. In addition, about 63,000 new cases of in situ breast cancer are expected in 2017 (2).
Male breast cancer accounts for about 1% of total cases; about 2500 new cases of invasive breast cancer and > 450 deaths from it are expected in 2017. In men, manifestations, diagnosis, and management are the same, although men tend to present later.
· 1. National Cancer Institute: Cancer Among Women. Accessed 1/18/18.
· 2. American Cancer Society: Breast Cancer Facts and Figures 2017–2018. Atlanta: American Cancer Society, Inc. 2017. Accessed on 1/18/18.
For women in the US, cumulative risk of developing breast cancer is 12% (1 in 8) by age 95. Much of the risk is incurred after age 60 (see Table: Risk of Being Diagnosed With Invasive Breast Cancer). These statistics can be misleading because most people die before age 95, and cumulative risk of developing the cancer in any 20-yr period is considerably lower. Risk of dying of breast cancer is about 9% 5 yr after diagnosis (1).
Risk of Being Diagnosed With Invasive Breast Cancer
Data from 2012–14. Based on the seer.cancer.gov web site. Accessed on 1/18/18.
· Family history: Having a 1st-degree relative (mother, sister, daughter) with breast cancer doubles or triples risk of developing the cancer, but breast cancer in more distant relatives increases risk only slightly. When ≥ 2 1st-degree relatives have breast cancer, risk may be 5 to 6 times higher.
· Breast cancer gene mutation: About 5 to 10% of women with breast cancer carry a mutation in one of the 2 known breast cancer genes, BRCA1 or BRCA2. If relatives of such a woman also carry the mutation, they have a 50 to 85% lifetime risk of developing breast cancer. Women with BRCA1 mutations also have a 20 to 40% lifetime risk of developing ovarian cancer; risk among women with BRCA2 mutations is increased less. Women without a family history of breast cancer in at least 2 1st-degree relatives are unlikely to carry this mutation and thus do not require screening for BRCA1 and BRCA2 mutations. Men who carry a BRCA2 mutation also have an increased risk of developing breast cancer. The mutations are more common among Ashkenazi Jews. Women with BRCA1 or BRCA2 mutations may require closer surveillance or preventive measures, such as taking tamoxifen or raloxifene or undergoing double mastectomy.
· Breast changes: History of a lesion that required a biopsy increases risk slightly. Women with multiple breast masses but no histologic confirmation of a high-risk pattern should not be considered at high risk. Benign lesions that may slightly increase risk of developing invasive breast cancer include complex fibroadenoma, moderate or florid hyperplasia (with or without atypia), sclerosing adenosis, and papilloma. Risk is about 4 or 5 times higher than average in patients with atypical ductal or lobular hyperplasia and about 10 times higher if they also have a family history of invasive breast cancer in a 1st-degree relative. Increased breast density seen on screening mammography is associated with an increased risk of breast cancer.
· Lobular carcinoma in situ (LCIS): Having LCIS increases the risk of developing invasive carcinoma in either breast by about 25 times; invasive carcinoma develops in about 1 to 2% of patients with LCIS annually.
· Use of oral contraceptives: Oral contraceptive use increases risk very slightly (by about 5 more cases per 100,000 women). Risk increases primarily during the years of contraceptive use and tapers off during the 10 yr after stopping. Risk is highest in women who began to use contraceptives before age 20 (although absolute risk is still very low).
· Hormone therapy: Postmenopausal hormone (estrogen plus a progestin) therapy appears to increase risk modestly after only 3 yr of use (2). After 5 yr of use, the increased risk is about 7 or 8 more cases per 10,000 women for each year of use (about a 24% increase in relative risk). Use of estrogen alone does not appear to increase risk of breast cancer (as reported in the Women's Health Initiative). Selective estrogen-receptor modulators (eg, raloxifene) reduce the risk of developing breast cancer.
· Diet: Diet may contribute to development or growth of breast cancers, but conclusive evidence about the effect of a particular diet (eg, one high in fats) is lacking. Obese postmenopausal women are at increased risk, but there is no evidence that dietary modification reduces risk. For obese women who are menstruating later than normal, risk may be decreased.
· 1. American Cancer Society: Breast Cancer Facts and Figures 2017–2018. Atlanta: American Cancer Society, Inc. 2017. Accessed on 1/18/18.
· 2. Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (3):321–333, 2002.
Most breast cancers are epithelial tumors that develop from cells lining ducts or lobules; less common are nonepithelial cancers of the supporting stroma (eg, angiosarcoma, primary stromal sarcomas, phyllodes tumor).
· Ductal carcinoma in situ (DCIS): About 85% of carcinoma in situ are this type. DCIS is usually detected only by mammography. It may involve a small or wide area of the breast; if a wide area is involved, microscopic invasive foci may develop over time.
· Lobular carcinoma in situ (LCIS): LCIS is often multifocal and bilateral. There are 2 types: classic and pleomorphic. Classic LCIS is not malignant but increases risk of developing invasive carcinoma in either breast. This nonpalpable lesion is usually detected via biopsy; it is rarely visualized with mammography. Pleomorphic LCIS behaves more like DCIS; it should be excised to negative margins.
Invasive carcinoma is primarily adenocarcinoma. About 80% is the infiltrating ductal type; most of the remaining cases are infiltrating lobular. Rare types include medullary, mucinous, metaplastic, and tubular carcinomas. Mucinous carcinoma tends to develop in older women and to be slow growing. Women with these types of breast cancer have a much better prognosis than women with other types of invasive breast cancer.
Inflammatory breast cancer is a fast-growing, often fatal cancer. Cancer cells block the lymphatic vessels in breast skin; as a result, the breast appears inflamed, and the skin appears thickened, resembling orange peel (peau d’orange). Usually, inflammatory breast cancer spreads to the lymph nodes in the armpit. The lymph nodes feel like hard lumps. However, often no mass is felt in the breast itself because this cancer is dispersed throughout the breast.
Paget disease of the nipple (not to be confused with the metabolic bone disease also called Paget disease) is a form of ductal carcinoma in situ that extends into the skin over the nipple and areola, manifesting with a skin lesion (eg, an eczematous or a psoriaform lesion). Characteristic malignant cells called Paget cells are present in the epidermis. Women with Paget disease of the nipple often have underlying invasive or in situ cancer.
Breast cancer invades locally and spreads through the regional lymph nodes, bloodstream, or both. Metastatic breast cancer may affect almost any organ in the body—most commonly, lungs, liver, bone, brain, and skin.
Estrogen and progesterone receptors, present in some breast cancers, are nuclear hormone receptors that promote DNA replication and cell division when the appropriate hormones bind to them. Thus, drugs that block these receptors may be useful in treating tumors with the receptors. About two thirds of postmenopausal patients with cancer have an estrogen-receptor positive (ER+) tumor. Incidence of ER+ tumors is lower among premenopausal patients.
Another cellular receptor is human epidermal growth factor receptor 2 (HER2; also called HER2/neu or ErbB2); its presence correlates with a poorer prognosis at any given stage of cancer. In about 20% of patients with breast cancer, HER2 receptors are overexpressed. Drugs that block these receptors are part of standard treatment for these patients.
Many breast cancers are discovered as a mass by the patient or during routine physical examination or mammography. Less commonly, the presenting symptom is breast pain or enlargement or a nondescript thickening in the breast.
Paget disease of the nipple manifests as skin changes, including erythema, crusting, scaling, and discharge; these changes usually appear so benign that the patient ignores them, delaying diagnosis for a year or more. About 50% of patients with Paget disease of the nipple have a palpable mass at presentation.
A common finding during physical examination is asymmetry or a dominant mass—a mass distinctly different from the surrounding breast tissue. Diffuse fibrotic changes in a quadrant of the breast, usually the upper outer quadrant, are more characteristic of benign disorders; a slightly firmer thickening in one breast but not the other may be a sign of cancer.
Inflammatory breast cancer is characterized by peau d'orange, erythema, and enlargement of the breast, often without a mass. A nipple discharge is common. Inflammatory breast cancer has a particularly aggressive course.
All women should be screened for breast cancer (1). All professional societies and groups agree on this concept, although they differ on the recommended age at which to start screening and the precise frequency of screening.
Mammography is more accurate in older women, partly because with aging, fibroglandular tissue in breasts tends to be replaced with fatty tissue, which can be more easily distinguished from abnormal tissue. Mammography is less sensitive in women with dense breast tissue, and some states mandate informing patients that they have dense breast tissue when it is detected by screening mammography.
Screening mammography guidelines for women with average risk of breast cancer vary, but generally, screening starts at age 40, 45, or 50 and is repeated every year or two until age 75 or life expectancy is < 10 yr (see Table: Recommendations for Breast Cancer Screening Mammography in Women With Average Risk). Clinicians should make sure that patients understand what their individual risk of breast cancer is and ask patients what their preference for testing is.
Recommendations for Breast Cancer Screening Mammography in Women With Average Risk
AAFP = American Academy of Family Physicians; ACOG = American College of Obstetricians and Gynecologists; ACP = American College of Physicians; ACR = American College of Radiology; ACS = American Cancer Society; NCCN = National Comprehensive Cancer Network; USPSTF = US Preventive Services Task Force.
The Breast Cancer Risk Assessment Tool (BCRAT), or Gail model, can be used to calculate a woman's 5-yr and lifetime risk of developing breast cancer. A woman is considered at average risk if her lifetime risk of breast cancer is < 15%.
Clinical Calculator: Gail Model for 5 Year Risk of Breast Cancer in Black Women (2007)
Clinical Calculator: Gail Model for 5 Year Risk of Breast Cancer (1999 paper)
Only about 10 to 15% of abnormalities detected on screening mammography result from cancer—an 85 to 90% false-positive rate. False-negative results may exceed 15%. Many of the false-positives are caused by benign lesions (eg, cysts, fibroadenomas), but there are new concerns about detecting lesions that meet histologic definitions of cancer but do not develop into invasive cancer during a patient's lifetime.
Accuracy depends partly on the techniques used and experience of the mammographer. Some centers use computer analysis of digitized mammography images (full-field digital mammography) to help in diagnosis. Such systems may be slightly more sensitive for invasive cancers in women < 50 when results are interpreted by radiologists, but probably not when interpreted primarily via computer detection.
Breast tomosynthesis (3-dimensional mammography), done with digital mammography, increases the rate of cancer detection slightly and decreases the rate of recall imaging (2); this test is helpful for women with dense breast tissue. However, the test exposes women to almost twice as much radiation as traditional mammography.
Although mammography uses low doses of radiation, radiation exposure has cumulative effects on cancer risk. When radiologic screening is started at a young age, risk of cancer is increased.
The value of routine clinical or breast self-examination remains controversial. Some societies such as the American Cancer Society and the US Preventive Services Task Force recommend against either modality for routine screening in average-risk women. Other societies including the American College of Obstetricians and Gynecologists advocate clinical and breast self-examination as important components of screening for breast cancer.
Clinical breast examination (CBE) is usually part of routine annual care for women > 40 (1). In the US, CBE augments rather than replaces screening mammography. However, in some countries where mammography is considered too expensive, CBE is the sole screen; reports on its effectiveness in this role vary.
Breast self-examination (BSE) alone has not been shown to reduce mortality rate, but evidence of its usefulness is mixed, and it is widely practiced. Because a negative BSE may tempt some women to forego mammography or CBE, the need for these procedures should be reinforced when BSE is taught. Patients should be instructed to do BSE on the same day each month. For menstruating women, 2 or 3 days after menses ends is recommended because breasts are less likely to be tender and swollen.
MRI is thought to be better than CBE or mammography for screening women with a high (eg, > 20%) risk of breast cancer, such as those with a BRCA gene mutation. For these women, screening should include MRI as well as mammography and CBE. MRI has higher sensitivity but may be less specific. Because specificity is lower, MRI is not considered appropriate for screening women with average or slightly increased risk.
· 1. The American College of Obstetricians and Gynecologists: Practice bulletin no. 122: Breast cancer screening. Obstet Gynecol 118 (2), part 1:372–382, 2011.
· 2. Friedewald SM, Rafferty EA, Rose SL, et al: Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA 311 (24):2499–2507, 2014. doi: 10.1001/jama.2014.6095.
Testing is required to differentiate benign lesions from cancer. Because early detection and treatment of breast cancer improves prognosis, this differentiation must be conclusive before evaluation is terminated.
If advanced cancer is suspected based on physical examination, biopsy should be done first; otherwise, the approach is the same as evaluation for a breast mass, which typically includes ultrasonography. All lesions that could be cancer should be biopsied. A prebiopsy bilateral mammogram may help delineate other areas that should be biopsied and provides a baseline for future reference. However, mammogram results should not alter the decision to do a biopsy if that decision is based on physical findings.
Pearls & Pitfalls
Percutaneous core needle biopsy is preferred to surgical biopsy. Core biopsy can be done guided by imaging or palpation (freehand). Routinely, stereotactic biopsy (needle biopsy guided by mammography done in 2 planes and analyzed by computer to produce a 3-dimensional image) or ultrasound-guided biopsy is being used to improve accuracy. Clips are placed at the biopsy site to identify it.
The excised specimen should be x-rayed, and the x-ray should be compared with the prebiopsy mammogram to determine whether all of the lesion has been removed. If the original lesion contained microcalcifications, mammography is repeated when the breast is no longer tender, usually 6 to 12 wk after biopsy, to check for residual microcalcifications.
After cancer is diagnosed, a multidisciplinary evaluation is usually done to plan further testing and treatment. The core multidisciplinary team typically includes a breast surgical oncologist, medical oncologist, and radiation oncologist plus other experts in cancer (tumor board).
Staging follows the TNM (tumor, node, metastasis) classification (see Table: Staging of Breast Cancer*). Because clinical examination and imaging have poor sensitivity for nodal involvement, staging is refined during surgery, when regional lymph nodes can be evaluated. However, if patients have palpably abnormal axillary nodes, preoperative ultrasonography-guided fine needle aspiration or core biopsy may be done:
Staging of Breast Cancer*
*For more information, see Giuliano AE, Connolly JI, Edge SB, et al: Breast Cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67 (4):290-303, 2017. doi: 10.3322/caac.21393 and the American Joint Committee on Cancer's 8th Edition Updates and Corrections. Accessed 1/18/18.
Tis = ductal carcinoma in situ or Paget disease of the nipple with no tumor (Paget disease with a tumor is classified by tumor size); T1 = tumor ≤ 2 cm; T1mi = tumor ≤ 0.1 cm; T2 = tumor > 2 but ≤ 5 cm; T3 = tumor > 5 cm; T4 =any size tumor with extension to chest wall and/or skin and with ulceration or skin nodules or inflammatory cancer.
NX = Nearby nodes not assessable (for example, because removed previously); N0 = no spread to nearby nodes or only isolated tumor cells; N1 = spread to 1–3 ipsilateral movable, low or midaxillary nodes and/or metastases detected by sentinel lymph node biopsy in clinically negative internal mammary lymph nodes (pN1); N1mi = N1 nodes with micrometastases (about 200 cells > 0.2 mm, but none > 2 mm); N2 = any of the following:
The 5-yr survival rate (from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program) depends on cancer stage:
· Absence of estrogen and progesterone receptors: Patients with ER+ tumors have a somewhat better prognosis and are more likely to benefit from hormone therapy. Patients with progesterone receptors on a tumor may also have a better prognosis. Patients with both estrogen and progesterone receptors on a tumor may have a better prognosis than those who have only one of these receptors, but this benefit is not clear.
· Presence of HER2 protein: When the HER2 gene (HER2/neu [erb-b2]) is amplified, HER2 is overexpressed, increasing cell growth and reproduction and often resulting in more aggressive tumor cells. Overexpression of HER2 is an independent risk factor for a poor prognosis; it may also be associated with high histologic grade, ER− tumors, greater proliferation, and larger tumor size, which are all poor prognostic factors.
· Presence of BRCA genes: For any given stage, patients with the BRCA1 gene appear to have a worse prognosis than those with sporadic tumors, perhaps because they have a higher proportion of high-grade, hormone receptor–negative cancers. Patients with the BRCA2 gene probably have the same prognosis as those without the genes if the tumors have similar characteristics. With either gene, risk of a 2nd cancer in remaining breast tissue is increased (to perhaps as high as 40%).